6-Thioguanine-induced growth arrest in 6-mercaptopurine-resistant human leukemia cells.

The thiopurines 6-thioguanine (6TG) and 6-mercaptopurine (6MP) are cytotoxic to proliferating cells by a mechanism involving incorporation into DNA via the purine salvage pathway, and resistance to these agents can be conferred by lack of the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase. However, human and murine hypoxanthine-guanine phosphoribosyltransferase-deficient leukemia cell lines have been shown to respond to 6TG by growth arrest and differentiation by a mechanism apparently not involving incorporation of 6TG into DNA. If so, leukemia cells resistant to 6MP should still respond to 6TG by growth arrest via an undescribed epigenetic mechanism. To test this, polyclonal 6MP-resistant variants were produced from three human leukemia cell lines, HL-60, U937, and CCRF-CEM. Treatment of both sensitive and resistant cells with 6TG induced growth arrest. The effect of 6TG in the 6MP-sensitive HL-60 and U937 cells was associated with significant loss of viability and DNA fragmentation. In contrast, the 6TG-treated 6MP-resistant cells exhibited a slower decline in viability and no DNA fragmentation. To identify the mechanism by which 6TG may induce growth arrest, tRNA was isolated from 6MP-resistant cells cultured for 48 h with 6TG. 6TG was found to be incorporated into tRNAs normally containing queuine in the anticodon wobble position. These studies may provide a basis for the development of new therapeutic regimens for the treatment of leukemia.

[1]  Y. Ling,et al.  Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. , 1992, Molecular pharmacology.

[2]  J. Ochieng,et al.  Altered queuine modification of transfer RNA involved in the in vitro transformation of Chinese hamster embryo cells. , 1989, Cancer research.

[3]  F. Mandelli,et al.  Treatment of recurrent promyelocytic leukemia with a combination regimen utilizing amsacrine, cytosine arabinoside and 6-thioguanine (AAT). , 1989, Haematologica.

[4]  K. Kretz,et al.  Guanine analog-induced differentiation of human promyelocytic leukemia cells and changes in queuine modification of tRNA , 1987, Molecular and cellular biology.

[5]  J. Maddocks,et al.  Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome. , 1985, British journal of clinical pharmacology.

[6]  B. Suter,et al.  Queuosine modification of the wobble base in tRNAHis influences ‘in vivo’ decoding properties. , 1985, The EMBO journal.

[7]  H. Kersten,et al.  Queuosine modification in tRNA and expression of the nitrate reductase in Escherichia coli. , 1984, The EMBO journal.

[8]  H. Kersten,et al.  Specific changes in lactate levels, lactate dehydrogenase patterns and cytochrome b559 in Dictyostelium discoideum caused by queuine. , 1984, European journal of biochemistry.

[9]  D. Housman,et al.  Induction of erythroid differentiation in vitro by purines and purine analogues , 1976, Cell.

[10]  N. Oppenheimer,et al.  Structure of the modified nucleoside Q isolated from Escherichia coli transfer ribonucleic acid. 7-(4,5-cis-Dihydroxy-1-cyclopenten-3-ylaminomethyl)-7-deazaguanosine. , 1975, Biochemistry.

[11]  A. D. Kelmers,et al.  Columns for rapid chromatographic separation of small amounts of tracer-labeled transfer ribonucleic acids. , 1971, Analytical biochemistry.

[12]  C. P. Rhoads,et al.  Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. , 1953, Blood.

[13]  N. Shindo-Okada,et al.  Recognition of UAG termination codon by mammalian tyrosine tRNA containing 6-thioqueuine in the first position of the anticodon. , 1985 .

[14]  S. Nishimura.  Structure, biosynthesis, and function of queuosine in transfer RNA. , 1983, Progress in nucleic acid research and molecular biology.